JP5576485B2 - 新生物疾患又は自己免疫疾患を処置するためのプロドラッグとしてのフラザノベンゾイミダゾール - Google Patents
新生物疾患又は自己免疫疾患を処置するためのプロドラッグとしてのフラザノベンゾイミダゾール Download PDFInfo
- Publication number
- JP5576485B2 JP5576485B2 JP2012522131A JP2012522131A JP5576485B2 JP 5576485 B2 JP5576485 B2 JP 5576485B2 JP 2012522131 A JP2012522131 A JP 2012522131A JP 2012522131 A JP2012522131 A JP 2012522131A JP 5576485 B2 JP5576485 B2 JP 5576485B2
- Authority
- JP
- Japan
- Prior art keywords
- formula
- compound
- lower alkyl
- amino
- lower alkoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 *[C@@](C(O)=O)N* Chemical compound *[C@@](C(O)=O)N* 0.000 description 4
- GGYDTWWKEDLQLT-UHFFFAOYSA-N C[Si+](C)(C)CCOC[n]1c(-c2n[o]nc2N)nc2c1cccc2 Chemical compound C[Si+](C)(C)CCOC[n]1c(-c2n[o]nc2N)nc2c1cccc2 GGYDTWWKEDLQLT-UHFFFAOYSA-N 0.000 description 1
- OOBHASHFSFBYFD-UMSFTDKQSA-N N#CCCNc1n[o]nc1-c1nc(cccc2)c2[n]1CC(c(cc1)ccc1NC([C@H](CCCCNC(OCc1ccccc1)=O)NC(OCc1ccccc1)=O)=O)=O Chemical compound N#CCCNc1n[o]nc1-c1nc(cccc2)c2[n]1CC(c(cc1)ccc1NC([C@H](CCCCNC(OCc1ccccc1)=O)NC(OCc1ccccc1)=O)=O)=O OOBHASHFSFBYFD-UMSFTDKQSA-N 0.000 description 1
- LSFOZQQVTWFMNS-UHFFFAOYSA-N Nc(cc1)ccc1C(C[n]1c(-c2n[o]nc2NCCC#N)nc2c1cccc2)=O Chemical compound Nc(cc1)ccc1C(C[n]1c(-c2n[o]nc2NCCC#N)nc2c1cccc2)=O LSFOZQQVTWFMNS-UHFFFAOYSA-N 0.000 description 1
- QEPDSNAEMKSMGN-UHFFFAOYSA-N Nc1n[o]nc1-c1nc2ccccc2[nH]1 Chemical compound Nc1n[o]nc1-c1nc2ccccc2[nH]1 QEPDSNAEMKSMGN-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09166469 | 2009-07-27 | ||
| EP09166469.8 | 2009-07-27 | ||
| PCT/EP2010/060803 WO2011012577A1 (en) | 2009-07-27 | 2010-07-26 | Furazanobenzimidazoles as prodrugs to treat neoplastic or autoimmune diseases |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013500304A JP2013500304A (ja) | 2013-01-07 |
| JP2013500304A5 JP2013500304A5 (OSRAM) | 2013-05-30 |
| JP5576485B2 true JP5576485B2 (ja) | 2014-08-20 |
Family
ID=41226617
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012522131A Active JP5576485B2 (ja) | 2009-07-27 | 2010-07-26 | 新生物疾患又は自己免疫疾患を処置するためのプロドラッグとしてのフラザノベンゾイミダゾール |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US8802858B2 (OSRAM) |
| EP (1) | EP2459553B1 (OSRAM) |
| JP (1) | JP5576485B2 (OSRAM) |
| KR (1) | KR101758400B1 (OSRAM) |
| CN (1) | CN102471329B (OSRAM) |
| AU (1) | AU2010277688B2 (OSRAM) |
| BR (1) | BR112012001817B8 (OSRAM) |
| CA (1) | CA2767875C (OSRAM) |
| CY (1) | CY1115809T1 (OSRAM) |
| DK (1) | DK2459553T3 (OSRAM) |
| EA (1) | EA021380B1 (OSRAM) |
| ES (1) | ES2524119T3 (OSRAM) |
| HR (1) | HRP20141120T1 (OSRAM) |
| IL (1) | IL217195A (OSRAM) |
| MX (1) | MX336240B (OSRAM) |
| NZ (1) | NZ597376A (OSRAM) |
| PL (1) | PL2459553T3 (OSRAM) |
| PT (1) | PT2459553E (OSRAM) |
| RS (1) | RS53679B1 (OSRAM) |
| SI (1) | SI2459553T1 (OSRAM) |
| TW (1) | TWI457337B (OSRAM) |
| UA (1) | UA106763C2 (OSRAM) |
| WO (1) | WO2011012577A1 (OSRAM) |
| ZA (1) | ZA201200228B (OSRAM) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9366682B2 (en) * | 2011-01-21 | 2016-06-14 | Basilea Pharmaceutica Ag | Use of stathmin as a biomarker of drug response to furazanobenzimidazoles |
| DK2666014T3 (en) | 2011-01-21 | 2017-01-09 | Basilea Pharmaceutica Ag | USE OF GLU-tubulin as a biomarker of PHARMACEUTICAL RESPONSE TO FURAZANOBENZIMIDAZOLER |
| CA2822491C (en) | 2011-01-21 | 2023-02-14 | Basilea Pharmaceutica Ag | Bubr1 as a biomarker for furazanobenzimidazoles |
| WO2012113802A1 (en) | 2011-02-24 | 2012-08-30 | Basilea Pharmaceutica Ag | Use of acetylated tubulin as a biomarker of drug response to furazanobenzimidazoles |
| PT2691533T (pt) | 2011-03-29 | 2017-06-20 | Basilea Pharmaceutica Ag | Utilização de fosfo-akt como um biomarcador da resposta farmacológica |
| US9558575B2 (en) | 2012-02-28 | 2017-01-31 | Blackberry Limited | Methods and devices for selecting objects in images |
| ITRM20130248A1 (it) * | 2013-04-24 | 2014-10-25 | Medivis S R L | Formulazioni di riboflavina per il cross-linking transepiteliale. |
| WO2015173341A1 (en) * | 2014-05-13 | 2015-11-19 | Basilea Pharmaceutica Ag | Dosage principle for anti-cancer furazanylbenzimidazoles |
| JP7034072B2 (ja) | 2015-10-22 | 2022-03-11 | バジリア・ファルマスーチカ・インターナショナル・アーゲー | 薬物応答のバイオマーカーとしてのｅｂ１の使用 |
| AU2018254010B2 (en) * | 2017-04-20 | 2022-05-12 | Pi Industries Ltd. | Novel phenylamine compounds |
| CN116947836A (zh) * | 2017-04-26 | 2023-10-27 | 巴斯利尔药物国际股份公司 | 制备呋咱并苯并咪唑及其晶型的方法 |
| WO2018210868A1 (en) | 2017-05-16 | 2018-11-22 | Basilea Pharmaceutica International AG | Novel dosage principle for drugs useful for treating neoplastic diseases |
| US11419856B2 (en) | 2017-11-20 | 2022-08-23 | Basilea Pharmaceutica International AG | Pharmaceutical combinations for use in the treatment of neoplastic diseases |
| EP3853224A1 (en) | 2018-09-20 | 2021-07-28 | Basilea Pharmaceutica International AG | Pharmaceutical combinations for use in the treatment of neoplastic diseases |
| WO2021048135A1 (en) | 2019-09-09 | 2021-03-18 | Basilea Pharmaceutica International AG | Pharmaceutical combinations comprising a furazanobenzimidazoles and a cd40 agonist for use in the treatment of neoplastic diseases |
| CN111454254B (zh) | 2020-04-26 | 2023-06-02 | 云白药征武科技(上海)有限公司 | 一种具有含氟取代基的苯并咪唑衍生物的制备及其应用 |
| CN111423429A (zh) * | 2020-05-19 | 2020-07-17 | 江西科技师范大学 | 苯并咪唑联呋咱类系列化合物及其合成方法 |
| WO2022053549A1 (en) | 2020-09-10 | 2022-03-17 | Basilea Pharmaceutica International AG | Use of c-myc as a biomarker of drug response |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6897208B2 (en) * | 2001-10-26 | 2005-05-24 | Aventis Pharmaceuticals Inc. | Benzimidazoles |
| WO2003066629A2 (en) * | 2002-02-06 | 2003-08-14 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds useful as inhibitors of gsk-3 |
| CN100434428C (zh) * | 2003-05-23 | 2008-11-19 | 巴斯利尔药物股份公司 | 呋咱并苯并咪唑类化合物 |
| US20070167505A1 (en) * | 2004-02-11 | 2007-07-19 | Basilea Pharmaceutica Ag | Substituted benzimidazoles and their use for inducing apoptosis |
-
2010
- 2010-07-26 NZ NZ597376A patent/NZ597376A/en not_active IP Right Cessation
- 2010-07-26 CN CN201080033104.2A patent/CN102471329B/zh active Active
- 2010-07-26 SI SI201030829T patent/SI2459553T1/sl unknown
- 2010-07-26 DK DK10740196.0T patent/DK2459553T3/da active
- 2010-07-26 RS RS20140669A patent/RS53679B1/sr unknown
- 2010-07-26 HR HRP20141120AT patent/HRP20141120T1/hr unknown
- 2010-07-26 KR KR1020127005138A patent/KR101758400B1/ko active Active
- 2010-07-26 ES ES10740196.0T patent/ES2524119T3/es active Active
- 2010-07-26 PL PL10740196T patent/PL2459553T3/pl unknown
- 2010-07-26 CA CA2767875A patent/CA2767875C/en active Active
- 2010-07-26 US US13/384,467 patent/US8802858B2/en active Active
- 2010-07-26 MX MX2012000611A patent/MX336240B/es unknown
- 2010-07-26 EA EA201200189A patent/EA021380B1/ru unknown
- 2010-07-26 EP EP10740196.0A patent/EP2459553B1/en active Active
- 2010-07-26 PT PT107401960T patent/PT2459553E/pt unknown
- 2010-07-26 BR BR112012001817A patent/BR112012001817B8/pt active IP Right Grant
- 2010-07-26 AU AU2010277688A patent/AU2010277688B2/en active Active
- 2010-07-26 JP JP2012522131A patent/JP5576485B2/ja active Active
- 2010-07-26 UA UAA201201704A patent/UA106763C2/uk unknown
- 2010-07-26 WO PCT/EP2010/060803 patent/WO2011012577A1/en not_active Ceased
- 2010-07-27 TW TW099124742A patent/TWI457337B/zh active
-
2011
- 2011-12-25 IL IL217195A patent/IL217195A/en active IP Right Grant
-
2012
- 2012-01-11 ZA ZA2012/00228A patent/ZA201200228B/en unknown
-
2014
- 2014-12-03 CY CY20141101010T patent/CY1115809T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5576485B2 (ja) | 新生物疾患又は自己免疫疾患を処置するためのプロドラッグとしてのフラザノベンゾイミダゾール | |
| US7951957B2 (en) | Substituted benzimidazoles and their use for inducing apoptosis | |
| ES2405054T3 (es) | Derivados de pirazol-1,2,4-oxadiazol como agonistas de esfingosina-1-fosfato | |
| CA2526026C (en) | Furazanobenzimidazoles | |
| AU2019331665A1 (en) | Heterocyclic compounds as AHR modulators | |
| JP2014532656A (ja) | 炎症および免疫関連用途のための化合物 | |
| JP2018522899A (ja) | ベンジリデングアニジン誘導体と化学療法剤の併用による癌の治療方法 | |
| HK1166316B (en) | Furazanobenzimidazoles as prodrugs to treat neoplastic or autoimmune diseases | |
| JP7616609B2 (ja) | Ｒｎａウイルス感染症を処置する為のアリール－ｎ－アリール誘導体 | |
| WO2024099226A1 (zh) | 含苯联杂芳基的二氢喋啶酮衍生物及其用途 | |
| JP2008308434A (ja) | １，３−ベンゾチアジノン誘導体およびその用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130408 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20130408 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20140522 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20140610 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20140703 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5576485 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |